Breathing With Amyotrophic Lateral Sclerosis

NCT05819931 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Toulouse

Phase

Not applicable

Started

2023-08-29

Last updated

2026-05-12

Condition(s) studied

Amyotrophic Lateral Sclerosis

Investigational drug(s) / intervention(s)

Mechanical In-Exsufflator treatment

Mechanical In-Exsufflator treatment: The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day. Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions. The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider. The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful. The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.

Study summary

The study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of Amyotrophic Lateral Sclerosis (ALS) patients evaluated via peak expiratory flow on cough (PEFC) measurements. The evolution of their PEFC is monitored to see if the curative management can have a positive impact on the latter.

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * Confirmed ALS categorized as probable or certain according to the revised Awaji-Shima criteria \[27\]. * ALS of spinal, bulbar or respiratory forms * Peak Flow measure between 160 and 255 L/min (recommendation of MIE in case of congestion, with the possibility of daily sessions) * Patient who has not benefited from treatment by MIE in the past year (less than 10 sessions in total) * Patient able to use the MIE and perform the collection, or having a caregiver able to help * Patient receiving physiotherapist treatment greater than or equal to twice a week Exclusion Criteria: * Psychiatric (DSM-5) or cognitive disorders incompatible with participation in the study * Contraindication to the use of an MIE (pneumothorax for example) * Insufficient level in French for understanding the study and completing the questionnaires * Current or past participation in another innovative research or care program relating to respiratory functions * Emergency situation for which the MIE must be set up within less than a week Exclusion during the study : * Appearance of a serious contraindication to the practice of MIE during the study (for example rib fracture during a fall) * Patient's physiotherapist refusing to do the study

Primary outcome measure(s)

cough peak expiratory flow evolution — 4 weeks post treatment initiation
evolution of respiratory function by peak expiratory flow on cough (PEFC) after 4 weeks of treatment with Mechanical In-Exsufflator (3 weekly sessions for two weeks then one daily session for 2 weeks) in ALS patients presenting with a poorly effective cough (Cough Peak Expiratory Flow between 160 and 255) and having an indication of punctual MIE. Ratio between the PEFC 4 weeks post treatment initiation and PEFC at baseline can show decrease in respiratory function if \<1 ; increase in respiratory functions if \>1 and a conservation of respiratory function if = 1. A PEFC remaining within 10% of its initial value (rounded to the nearest ten) is considered unmodified

Trial sites (1)

Facility	City	Region	Status
SLA Center - Purpan University Hospital Toulouse, FRANCE	Toulouse	Occitanie	Recruiting

More University Hospital, Toulouse trials in France

Feasibility and Benefits of Reflexology in the Prevention of Neuropathy Induced by Oxaliplatin in Colorectal Cancer Recruiting

Adapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity Recruiting

Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients With Systemic sclEroderma Starting soon

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse Recruiting

Paramedical Tele-education on Moderate Depressive Episodes Recruiting

Other trials for the same condition

Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments Recruiting

ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach Active, not recruiting

Staging System in Amyotrophic Lateral Sclerosis Active, not recruiting

Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality Recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05819931 on ClinicalTrials.gov ↗ ← All trials in France